Envision Pharma Group
9.5.2023 13:02:01 CEST | ACCESS Newswire | Press release
PHILADELPHIA, PA / ACCESSWIRE / May 9, 2023 / Envision Pharma Group (Envision) today announced the appointment of Dr. Deepti Sodhi Jaggi to the Envision Board of Directors.
"We are pleased to welcome Deepti to the Envision Board of Directors," shares Meg Heim, CEO of Envision Pharma Group. "Deepti's deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner."
Dr. Jaggi's career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.
Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.
Dr. Jaggi's previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.
"I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives," says Dr. Jaggi.
Dr. Jaggi's educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business.
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.
Contact Information
Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856
SOURCE: Envision Pharma Group
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/753175/Envision-Pharma-Group-Announces-Appointment-of-Dr-Deepti-Sodhi-Jaggi-to-Board-of-Directors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release
Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort
GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release
Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort
Innodata to Report First Quarter 2026 Results15.4.2026 14:00:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report First Quarter 2026 results after the market closes on Thursday, May 7, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 715 9871 North America, Toll Free (+44) 800 358 0970 United Kingdom (+1) 646 307 1963 International Participant Access Code 3150581 For Replay: (+1) 800 770 2030 North America-Toll Free (+1) 609 800 9909 International Playback ID 3150581 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available
Innodata to Report First Quarter 2026 Results15.4.2026 14:00:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report First Quarter 2026 results after the market closes on Thursday, May 7, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 715 9871 North America, Toll Free (+44) 800 358 0970 United Kingdom (+1) 646 307 1963 International Participant Access Code 3150581 For Replay: (+1) 800 770 2030 North America-Toll Free (+1) 609 800 9909 International Playback ID 3150581 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available
Envision Pharma Group Strengthens Executive Leadership Team to Accelerate Growth, Innovation and Global Client Delivery15.4.2026 14:00:00 CEST | Press release
Two Senior Appointments Reinforce Commitment to Technology Integration and Scalable Pharmaceutical Services FAIRFIELD, CT / ACCESS Newswire / April 15, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed two senior executives to further strengthen its leadership team and focus on integrating innovative AI technologies across its portfolio to deliver more data-driven outcomes for clients. Jay Ferro has been appointed President, Technology and Chief Product Officer. He joins Envision from Clario, a global clinical trial endpoint and technology company, where he led platform modernization and operational transformation initiatives that helped position the company for its acquisition in October 2025. Ferro will oversee a combined technology and product organization responsible for shaping enterprise technology strategy, translating business needs into scalable product solutions, and ensuring investments align
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
